12:00 AM
 | 
Jan 28, 2002
 |  BioCentury  |  Product Development

Aranesp deal: A portent for JNJ?

Amgen Inc. has scored a coup in its efforts to break into the European erythropoietin market, winning a place for its Aranesp second generation EPO as the drug of choice for distribution by Fresenius Medical Care AG, Germany's leading dialysis specialist.

AMGN's Amgen GmbH subsidiary (Munich, Germany) last week signed an exclusive promotional support agreement with Fresenius (FSE:FME, Bad Homburg, Germany), which supplies kidney machines to 80% of all German dialysis clinics. Starting this month, FME's Fresenius Medical Care Deutschland GmbH subsidiary will promote Aranesp exclusively in Germany and will assist with the physical distribution and marketing efforts in cooperation with AMGN's sales force.

FME had obtained EPO exclusively from...

Read the full 535 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >